# Xenetic (XBIO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/XBIO
## Company Profile
- Ticker: XBIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.96 USD
- Market cap: 7743769.279999999 USD
- Last updated: 2026-08-05
## Business Overview
### DNase Oncology Platform
Xenetic Biosciences develops systemic DNase I therapies intended to dismantle extracellular DNA structures that support tumor progression and treatment resistance.
### Tumor Microenvironment Strategy
The platform targets neutrophil extracellular traps and other DNA-rich components of the tumor microenvironment that may promote metastasis and suppress immune activity.
### Translational Development
Xenetic is advancing investigator-sponsored research, biomarker work, manufacturing development, and clinical planning to establish the foundation for future oncology studies.
## Why The Stock Is Moving

The latest monitored company update is “Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- For Xenetic, the near-term story still runs through its latest development priorities. Recent commentary puts the focus on Generated robust translational data supporting the DNase I platform across multiple oncology settings Completed process improvement and analytical development activities.... That leaves the stock tied to whether the next milestone lands on schedule.

## Recent News
- 2026-08-07 12:35 EST — [Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-second-quarter-2026-financial-results-and-highlights-1142fce8) — Source: Xenetic
- 2026-06-04 12:40 EST — [Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma) — Source: Xenetic
- 2026-06-01 13:02 EST — [Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival) — Source: Xenetic
- 2026-05-13 12:05 EST — [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-continued-advancement-of-dnase-oncology-platform) — Source: Xenetic
- 2026-04-22 13:00 EST — [Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting) — Source: Xenetic